Edgar Filing: Edge Therapeutics, Inc. - Form 4

Edge Thera Form 4	peutics, Inc.										
March 15, 2	2017										
FORM	ЛЛ						E COMMISSIO		PPROVAL		
	N OMB Number:	3235-0287									
Check t if no lor subject Section Form 4 Form 5	nger STATEN to STATEN 16. or	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES									
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type	Responses)										
1. Name and Leuthner B	Symbol	er Name ar		-	5. Relationship of Reporting Person(s) to Issuer						
		Edge T	Therapeut	ics, Inc. [EDGE]	(Check all applicable)					
(Last) (First) (Middle) 300 CONNELL DRIVE,, SUITE 4000			3. Date of Earliest Transaction (Month/Day/Year) 03/13/2017				X Director 10% Owner X Officer (give title Other (specify below) below) President and CEO				
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 				
BERKELE	Y HEIGHTS, NJ	07922					Form filed by Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	Code (Instr. 8)	4. Securi onAcquired Disposed (Instr. 3, Amount	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
D											
Reminder: Re	port on a separate line	e tor each cl	ass of sec	urities bend	Perso infor requi	ons who re nation con red to resp ays a curre	or indirectly. spond to the collect tained in this form ond unless the fo ently valid OMB co	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Edge Therapeutics, Inc. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8	Di	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount o Number o Shares
Stock Option (right To Purchase)	\$ 8.86	03/13/2017		A	20	67,500		<u>(1)</u>	03/13/2027	Common Stock	267,50

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Leuthner Brian A 300 CONNELL DRIVE, SUITE 4000 BERKELEY HEIGHTS, NJ 07922	Х		President and CEO					
Signatures								
/s/ Albert N. Marchio II, attorney-in-fact		03/15/2017						
**Signature of Reporting Person		Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option, representing a right to purchase a total of 267,500 shares of Common Stock, will become exercisable on February 17, 2018,

(1) with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.